In recent years, HDAC6 has been the sole member of Class II HDACs that has been widely studied for its role in IPF, and novel selective HDAC6 inhibitors have been developed and tested against models of the disease [27]. Here, HDAC6 is linked to idiopathic pulmonary fibrosis.